Dutasteride Treatment for the Reduction of Heavy Drinking in Men

Dutasteride Treatment for the Reduction of Heavy Drinking

This study will examine the safety and potential benefit of the medication dutasteride to help men reduce or stop drinking alcohol.

Study Overview

• Status: Completed
• Conditions: Alcohol Dependence; Alcoholism; Alcohol Abuse
• Intervention / Treatment: Drug: Dutasteride; Drug: sugar pill

Detailed Description

Extensive preclinical studies indicate that neuroactive steroids medicate important effects of alcohol and support the examination of neuroactive steroid modulators as treatment options for alcohol use problems. Dutasteride, a widely prescribed medication for benign prostatic hypertrophy, blocks a key step in the production of neuroactive steroids and represents a promising candidate for treatment of alcohol use disorders. This study will use a 12-week randomized placebo controlled design to examine the safety and efficacy of dutasteride to reduce drinking among a sample of 160 men with hazardous levels of alcohol use. It will additionally examine the potential moderation of dutasteride treatment effects by a common missense polymorphism in a neuroactive steroid biosynthetic enzyme that we have previously reported to be associated with alcohol dependence. Identification of genetic predictors of medication response offers the potential for matching alcohol treatment medications with those most likely to respond.

• Study Type: Interventional
• Enrollment (Actual): 189
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Connecticut
    • Farmington, Connecticut, United States, 06030
      • University of Connecticut Health Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• an average weekly ethanol consumption of at least 24 standard drinks;
• be able to read English at the 8th grade or higher level;
• no evidence of significant cognitive impairment;
• be willing to provide signed, informed consent to participate in the study (including a willingness to stop or reduce drinking to non-hazardous levels);
• be willing to nominate an individual who will know the patient's whereabouts to facilitate follow up during the study

Exclusion Criteria:

• history of significant alcohol withdrawal symptoms (e.g. substantial tremor, autonomic changes, perceptual distortions, seizures, delirium, or hallucinations);
• current Diagnostic and Statistical Manual Version IV (DSM-IV) diagnosis of Alcohol Dependence who on clinical examination by a physician, are deemed to be too severely alcohol dependent to permit them to participate in a placebo-controlled study (e.g. evidence of serious adverse medical or psychiatric effects that are exacerbated by heavy drinking and would, for safety reasons, lead the physician to urge the patient to be totally abstinent and engage in an empirically supported treatment).
• current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation,(we will not exclude patients with hypertension, diabetes mellitus, asthma or other common medical conditions, if these are adequately controlled and the patient has an ongoing relationship with a primary care provider)
• serious psychiatric illness on the basis of history or psychiatric examination (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, organic mental disorder, current clinically significant eating disorder, or substantial suicide or violence risk);
• current DSM-IV diagnosis of drug dependence (other than nicotine dependence);
• currently taking psychotropics other than medication for depression/anxiety disorder (with stable dose for at least 4 weeks),medications for treatment of Attention Deficit/Hyperactivity Disorder (with stable dose for at least 4 weeks), a non-benzodiazepine sleep medication or a low dose of benzodiazepine equivalent to 2 mg clonazepam or lorazepam per day;
• are considered by the investigators to be an unsuitable candidate for receipt of an investigational drug

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: dutasteride; 4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.	Drug: Dutasteride; Other Names: Avodart
Placebo Comparator: Sugar Pill; Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.	Drug: sugar pill; Other Names: placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Heavy Drinking Days Per Week	Number of days / study week with 5 or more drinks consumed	12-week treatment period
Drinks Per Week	Total number of drinks aggregated by week	12-week treatment period
Number of Participants With no Heavy Drinking Days	Number of participants with no heavy drinking days (days with 5 or more drinks) during the last 4 weeks of treatment.	Last 4 weeks of treatment
Number of Participants With no Hazardous Drinking	Number of participants with no hazardous drinking (not more than 4 drinks on one day and not more than 14 drinks per week) during the last 4 weeks of treatment.	Last 4 weeks of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HDD/ Week by Treatment Group and AKR1C3*2 Genotype	Change in Number of days / week with 5 or more drinks consumed contrasting AKR1C3*2 CC vs. G-carrier genotype and treatment group	12-week treatment period
Carbohydrate-deficient Transferrin	Carbohydrate-deficient transferrin (CDT) at end of treatment as percentage of baseline. Serum CDT is a biochemical measure of heavy alcohol use.	end of 12-week treatment vs. baseline

Collaborators and Investigators

• Sponsor: UConn Health
• Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Investigators: Principal Investigator: Jonathan Covault, M.D., PhD., UConn Health

Study record dates

Study Major Dates

• Study Start: January 1, 2013
• Primary Completion (Actual): February 28, 2018
• Study Completion (Actual): February 28, 2018

Study Registration Dates

• First Submitted: December 24, 2012
• First Submitted That Met QC Criteria: December 31, 2012
• First Posted (Estimate): January 1, 2013

Study Record Updates

• Last Update Posted (Actual): April 26, 2019
• Last Update Submitted That Met QC Criteria: April 11, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: neuroactive steroids
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Alcohol-Related Disorders; Substance-Related Disorders; Alcoholism; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Steroid Synthesis Inhibitors; 5-alpha Reductase Inhibitors; Dutasteride
• Other Study ID Numbers: 13-056-2; 2P60AA003510 (U.S. NIH Grant/Contract)